Key | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Vodafone Group | 4.3% |
BP | 4.2% |
Other | 82.4% |
Name | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Vodafone Group | 4.3% |
BP | 4.2% |
Vodafone Group | 4.2% |
British American Tobacco | 3.4% |
Aberforth UK Small Companies | 3.2% |
HSBC Holdings PLC (UK Reg) | 2.9% |
BG Group | 2.3% |
AstraZeneca | 2.3% |
No asset data available.
Date | 30-Oct-2024 |
---|---|
NAV | 162.00p |
Currency | GBP |
Change | -2.20p |
% | -1.34% |
YTD change | 11.50p |
YTD % | 7.64% |
Fund Inception | 31/07/1998 |
---|---|
Fund Manager | HSBC Multimanager |
TER | 1.65 (15-Jan-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | £50 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.05 |
You are here: research